Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00219544 |
This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as Diabetic peripheral Neuropathy and Postherpetic Neuralgia).
Condition | Intervention | Phase |
---|---|---|
Neuropathic Pain |
Drug: Pregabalin (Lyrica) Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Peripheral Neuropathic Pain |
Enrollment: | 158 |
Study Start Date: | November 2005 |
Study Completion Date: | February 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Pregabalin (Lyrica)
pregabalin 150mg/day (150mg BID)
|
2: Experimental |
Drug: Pregabalin (Lyrica)
pregabalin 300 mg/day (75 mg BID)
|
3: Experimental |
Drug: Pregabalin (Lyrica)
pregabalin 600/day (300mg BID)
|
4: Placebo Comparator |
Drug: Placebo
Placebo
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Alberta | |
Pfizer Investigational Site | |
Calgary, Alberta, Canada, T2N 4N1 | |
Pfizer Investigational Site | |
Red Deer, Alberta, Canada, T4N 6V7 | |
Pfizer Investigational Site | |
Edmonton, Alberta, Canada, T5N 3Y6 | |
Pfizer Investigational Site | |
Edmonton, Alberta, Canada, T5J 3N4 | |
Pfizer Investigational Site | |
Calgary, Alberta, Canada, T3B 0M3 | |
Pfizer Investigational Site | |
Calgary, Alberta, Canada, T2S 3C3 | |
Canada, British Columbia | |
Pfizer Investigational Site | |
Kelowna, British Columbia, Canada, V1Y 2H4 | |
Pfizer Investigational Site | |
Vancouver, British Columbia, Canada, V6Z 2E8 | |
Pfizer Investigational Site | |
Vancouver, British Columbia, Canada, V6E 1M7 | |
Canada, Manitoba | |
Pfizer Investigational Site | |
Winnipeg, Manitoba, Canada, R2V 3P4 | |
Pfizer Investigational Site | |
Winnipeg, Manitoba, Canada, R3E 3P4 | |
Pfizer Investigational Site | |
Winnipeg, Manitoba, Canada, R3A 1R9 | |
Canada, Nova Scotia | |
Pfizer Investigational Site | |
Halifax, Nova Scotia, Canada, B3J 3T1 | |
Canada, Ontario | |
Pfizer Investigational Site | |
Port Hope, Ontario, Canada, L1A 3Y9 | |
Pfizer Investigational Site | |
Kingston, Ontario, Canada, K7L 2V7 | |
Pfizer Investigational Site | |
Toronto, Ontario, Canada, M5G 2N2 | |
Pfizer Investigational Site | |
London, Ontario, Canada, N6A 4V2 | |
Canada, Prince Edward Island | |
Pfizer Investigational Site | |
Charlottetown, Prince Edward Island, Canada, C1A 2M5 | |
Canada, Quebec | |
Pfizer Investigational Site | |
Ste-Foy, Quebec, Canada, G1V 4P9 | |
Pfizer Investigational Site | |
Sherbrooke, Quebec, Canada, J1H 5N4 | |
Pfizer Investigational Site | |
Montreal, Quebec, Canada, H3G 1A4 | |
Pfizer Investigational Site | |
Laval, Quebec, Canada, H7M 3L9 | |
Pfizer Investigational Site | |
Montreal, Quebec, Canada, H3T 1E2 | |
Pfizer Investigational Site | |
Levis, Quebec, Canada, G6V 3Z1 | |
Pfizer Investigational Site | |
Montreal, Quebec, Canada, H3A 2B4 | |
Pfizer Investigational Site | |
Sherbrook, Quebec, Canada, J1H 4J6 | |
Pfizer Investigational Site | |
Laval, Quebec, Canada, H7T 2P5 | |
Pfizer Investigational Site | |
Mirabel, Quebec, Canada, J7J 2K8 | |
Pfizer Investigational Site | |
Granby, Quebec, Canada, J2G 8Z9 | |
Canada, Saskatchewan | |
Pfizer Investigational Site | |
Saskatoon, Saskatchewan, Canada, S7N 0W8 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trials Disclosure Group ) |
Study ID Numbers: | A0081084 |
Study First Received: | September 13, 2005 |
Last Updated: | December 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00219544 |
Health Authority: | Canada: Health Canada |
Pregabalin Pain |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Peripheral Nervous System Agents |
Analgesics Central Nervous System Agents Anticonvulsants Pharmacologic Actions |